Arcus Biosciences, Inc.

NYSE:RCUS Stock Report

Market Cap: US$1.2b

Arcus Biosciences Future Growth

Future criteria checks 2/6

Arcus Biosciences is forecast to grow earnings and revenue by 20.5% and 26% per annum respectively. EPS is expected to grow by 23.9% per annum. Return on equity is forecast to be -98.1% in 3 years.

Key information

20.5%

Earnings growth rate

23.9%

EPS growth rate

Biotechs earnings growth27.2%
Revenue growth rate26.0%
Future return on equity-98.1%
Analyst coverage

Good

Last updated26 Nov 2024

Recent future growth updates

Recent updates

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Jan 13

Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS)

Dec 12
Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS)

Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking

Nov 21
Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking

Arcus Biosciences: Advancing On Several Fronts

Oct 29

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Sep 23

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 15
Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Aug 19
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10
Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18
Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Dec 15

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Nov 30
Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Aug 29

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08
Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05
Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

Earnings and Revenue Growth Forecasts

NYSE:RCUS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027280-429-358-2636
12/31/2026249-417-224-2509
12/31/2025216-386-453-36110
12/31/2024261-303-153-26910
9/30/2024263-270-169-158N/A
6/30/2024247-249-267-247N/A
3/31/2024237-231-235-210N/A
12/31/2023117-307-330-306N/A
9/30/2023120-293-306-288N/A
6/30/2023121-287-316-306N/A
3/31/2023119-279-326-314N/A
12/31/2022112-267426438N/A
9/30/202243380426446N/A
6/30/202240967447473N/A
3/31/202239258439464N/A
12/31/202138353-282-256N/A
9/30/202138-278-263-244N/A
6/30/202193-1991426N/A
3/31/202185-1687076N/A
12/31/202078-123108111N/A
9/30/202078-88150152N/A
6/30/202015-112-93-92N/A
3/31/202015-95-89-88N/A
12/31/201915-85-75-73N/A
9/30/20197-80-73-71N/A
6/30/20199-69-58-55N/A
3/31/20199-54-50-47N/A
12/31/20188-50-47-43N/A
9/30/20188-51-24-20N/A
6/30/20184-63N/A-33N/A
3/31/20183-59N/A-29N/A
12/31/20171-53N/A-25N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RCUS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RCUS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RCUS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RCUS's revenue (26% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: RCUS's revenue (26% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RCUS is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 02:11
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arcus Biosciences, Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Zhiqiang ShuBerenberg
Jason ZemanskyBofA Global Research